Dr. Daniel R. Rhodes, Ph.D, is the President and CEO and Co-founder of Strata Oncology. He is an experienced entrepreneur and life sciences executive with 15 years in cancer genomics, informatics and diagnostics. In 2006 he co-founded Compendia Bioscience, Inc., and served as its Chief Executive Officer. Dr. Rhodes led the original development of Oncomine and the Oncomine Concepts Map to several novel bioinformatics methods, including Meta-analysis of Microarrays and Cancer Outlier Profile Analysis (COPA). He served as Head of Oncology Strategy and led the Compendia business unit for Thermo Fisher. He also serves as Adjunct Assistant Research Professor in the Department of Pathology at the University of Michigan Medical School. He has received several awards for his work including the Harold Weintraub Award and the Team Science Award from the AACR. Dr. Rhodes also maintains a part-time faculty research position at the University of Michigan Center for Translational Pathology. He has an 8-year track record in cancer genomics and informatics with more than 30 papers published in peer-reviewed journals. Dr. Rhodes has contributed to several important advances in the field, including the seminal discovery of recurrent gene fusions in prostate cancer. Dr. Rhodes received a Ph.D. in Bioinformatics and Bachelor of Science in Molecular Biology from the University of Michigan.